Guidance and quality standards Awaiting development

Skip to filters Skip to results

Showing 1 to 50 of 353

Guidance and quality standards awaiting development
Title	Type
10395 - Aprocitentan for treating resistant hypertension TS ID 10395	Technology appraisal guidance
Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095	Technology appraisal guidance
Abdominal aortic aneurysm	Quality standard
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]	Technology appraisal guidance
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]	Technology appraisal guidance
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]	Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]	Technology appraisal guidance
Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma TS ID 11823	Technology appraisal guidance
Acne	Quality standard
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy TS ID 11904	Technology appraisal guidance
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339]	Technology appraisal guidance
Adalimumab for treating early Dupuytren's contracture TS ID 11870	Technology appraisal guidance
Adrenal dysfunction	Quality standard
Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care	Quality standard
Advocacy services for adults with health and social care needs	Quality standard
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]	Technology appraisal guidance
AI for fracture detection in the emergency department	Diagnostics guidance
AI-supported colorectal polyp detection	Health technology evaluation
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over TS ID 10680	Technology appraisal guidance
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830	Technology appraisal guidance
Ambulatory pulmonary artery pressure monitoring devices	Diagnostics guidance
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]	Technology appraisal guidance
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]	Technology appraisal guidance
Amyotrophic lateral sclerosis - SAR443820 TS ID 11938	Technology appraisal guidance
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]	Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer TS ID 11967	Technology appraisal guidance
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia	Medical technologies guidance
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774	Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer ID 6200	Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]	Technology appraisal guidance
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]	Technology appraisal guidance
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]	Technology appraisal guidance
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]	Technology appraisal guidance
Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer TSID 10710	Technology appraisal guidance
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration ID6401	Technology appraisal guidance
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]	Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]	Technology appraisal guidance
Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]	Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769	Technology appraisal guidance
Benralizumab for previously treated severe nasal polyps [ID1659]	Technology appraisal guidance
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over TS ID 11867	Technology appraisal guidance
Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266]	Technology appraisal guidance
Bentracimab for reversing the antiplatelet activity of ticagrelor TS ID 10550	Technology appraisal guidance
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]	Technology appraisal guidance
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]	Technology appraisal guidance
Bimekizumab for treating ankylosing spondylitis TS ID 10334	Technology appraisal guidance
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991	Technology appraisal guidance
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592	Technology appraisal guidance
Botulinum toxin type A for preventing episodic migraine TS ID 11939	Technology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma TS ID 11987	Technology appraisal guidance

Results per page

10
25
50
All